Gain detailed insights into the trading activity of Congress members for Biomarin Pharmaceutical on our government trades page. Stay updated on how elected officials are investing in BMRN.

Biomarin Pharmaceutical - Government Trades

Biomarin Pharmaceutical

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Worst Performing

Large Cap

News

Movers

BMRN

New Oriental Education & Technology Group

MUFG

NICE

RIVN

Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw significant decreases.

Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)

Framingham,,Ma,Usa,-,January,18,,2024:,Walmart,Store,Exterior.

Price Target

Markets

Trading Ideas

AMAT

GLOB

TTWO

Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday

Caterpillar - logo

ACON

AIRE

ATNI

BNAI

BPTS

BRFH

BRKL

CDTX

CSSE

CYCC

ESGL

FCFS

HRYU

HUIZ

ILAG

JAKK

OPTN

ORGO

PCSA

POAI

PTSI

SGBX

SNBR

SPCB

STRA

ULBI

ZAPP

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Analyst Color

Biotech

Health Care

Hedge Funds

Management

Analyst Ratings

General

Activist investor Elliott Investment Management has taken a significant position in BioMarin Pharmaceutical Inc (NASDAQ: BMRN), engaging with the company on its strategic direction amid leadership changes and the evolving status of its 

Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO Change

Penny Stocks

Small Cap

Intraday Update

APPN

AUGX

DCGO

DDOG

DOCN

EVER

GDEV

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MGNX

MTTR

MYGN

OLPX

OSCR

PLNT

PRAA

ROVR

SGRY

SNOW

TASK

TMDX

TRIP

TWKS

VERV

VMEO

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.

Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday

Earnings

PTCT

In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a 

Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?

Initiation

ASND

BBIO

Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in 

Impact on BioMarin&#39;s Sentiment: Voxzogo&#39;s Triumph Clouded by Uncertainty

Guidance

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q2 adjusted EPS of $0.54, higher than $0.41 a year ago and beating the 

Biomarin&#39;s Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand

Upgrades

BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ: BMRN) to Outperform from Market Perform, and the price target remains at $102, 

BioMarin Presents ~20% Upside Amid Voxzogo&#39;s Success and Slow Roctavian Uptake, Analyst Says

On Thursday, The FDA approved BioMarin Pharmaceutical Inc&#39;s (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults 

BioMarin&#39;s Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical Inc

Ratings for Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $100.7, a high estimate of $115.00, and a low estimate of $72.00. A decline of 1.17% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1721667640_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Biomarin Pharmaceutical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Biomarin Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Biomarin Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biomarin Pharmaceutical analyst ratings.</a>
<h2>Delving into Biomarin Pharmaceutical's Background</h2>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Understanding the Numbers: Biomarin Pharmaceutical's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Biomarin Pharmaceutical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.79% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of 13.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.77%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Biomarin Pharmaceutical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.29% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.22, Biomarin Pharmaceutical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and maintains $110 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) has outperformed the market over the past 20 years by 6.44% on an annualized basis producing an average annual return of 14.87%. Currently, Biomarin Pharmaceutical has a market capitalization of $16.09 billion. 
Buying $100 In BMRN: If an investor had bought $100 of BMRN stock 20 years ago, it would be worth $1,718.66 today based on a price of $84.73 for BMRN at the time of writing.
<h3>Biomarin Pharmaceutical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721322021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) has outperformed the market over the past 20 years by 6.65% on an annualized basis producing an average annual return of 15.22%. Currently, Biomarin Pharmaceutical has a market capitalization of $16.31 billion. 
Buying $1000 In BMRN: If an investor had bought $1000 of BMRN stock 20 years ago, it would be worth $16,360.00 today based on a price of $85.89 for BMRN at the time of writing.
<h3>Biomarin Pharmaceutical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721165646_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today

Biomarin Pharmaceutical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NYSE">BMRN</a>) short percent of float has risen 17.39% since its last report. The company recently reported that it has 3.56 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Biomarin Pharmaceutical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720120520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Biomarin Pharmaceutical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Biomarin Pharmaceutical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Biomarin Pharmaceutical's peer group average for short interest as a percentage of float is 6.35%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Biomarin Pharmaceutical's Recent Short Interest

9 analysts have expressed a variety of opinions on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $99.67, a high estimate of $115.00, and a low estimate of $72.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.2%. 
<img src="https://www.benzinga.com/files/images/story/2024/1719504091_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Biomarin Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Biomarin Pharmaceutical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Biomarin Pharmaceutical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Biomarin Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biomarin Pharmaceutical analyst ratings.</a>
<h2>About Biomarin Pharmaceutical</h2>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Unraveling the Financial Story of Biomarin Pharmaceutical</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Biomarin Pharmaceutical displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 8.79%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.66%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.77%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Biomarin Pharmaceutical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.29%, the company showcases efficient use of assets and strong financial health.
Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average at 0.22, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and raises the price target from $110 to $115.

Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $115

New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with Achondroplasia
Phase 2 and 3 Data on VOXZOGO Demonstrate Safety, Efficacy and Impact on Proportionality and Health-Related Quality of Life for Children with Achondroplasia
New Research Underscores Unmet Medical Needs of People with Hypochondroplasia
SAN RAFAEL, Calif., June 17, 2024 /PRNewswire/ --&nbsp;BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO&#xAE; experienced increases in bone length while maintaining bone strength. The data will be presented at the 11th International Conference on Children's Bone Health (ICCBH) in Salzburg, Austria, June 22-25, 2024. BioMarin will also share the first results from a study underscoring the unmet medical needs of people living with hypochondroplasia.

BioMarin Presents Data Highlighting Impact Of VOXZOGO In Bone Health And Health-Related Quality Of Life In Achondroplasia At 2024 ICCBH

WIIM

BioMarin Pharmaceutical shares are trading higher after it was announced the company will join the S&P MidCap 400.

Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression Maintained Four Years Post-ROCTAVIAN Infusion
Additional Data Show Meaningful Impact of ROCTAVIAN on Health-Related Quality of Life (HRQoL)&nbsp;
SAN RAFAEL, Calif., June 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced that new data supporting the long-term safety and efficacy of ROCTAVIAN&#xAE; (valoctocogene roxaparvovec-rvox) will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand, June 22-26, 2024.

BioMarin Presents New Phase 3, 4-Year Data Underscoring Long-Term Safety And Efficacy Of ROCTAVIAN At International Society On Thrombosis And Haemostasis 2024 Congress In Bangkok, Thailand, June 22-26, 2024

Disclosed in a recent SEC filing on June 4, MEIER, Board Member at Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001048477/000104847724000116//Archives/edgar/data/1048477/000104847724000116/0001048477-24-000116-index.htm">U.S. Securities and Exchange Commission</a>, MEIER, Board Member at Biomarin Pharmaceutical, exercised stock options for 6,600 shares of BMRN. The transaction value amounted to $104,412.
Biomarin Pharmaceutical shares are currently trading down by 0.21%, with a current price of $78.92 as of Wednesday morning. This brings the total value of MEIER's 6,600 shares to $104,412.
<h3>Delving into Biomarin Pharmaceutical's Background</h3>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Financial Milestones: Biomarin Pharmaceutical's Journey</h3>
Revenue Growth: Biomarin Pharmaceutical displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 8.79%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 80.71%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Biomarin Pharmaceutical's EPS is below the industry average. The company faced challenges with a current EPS of 0.47. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.22.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: Biomarin Pharmaceutical's current Price to Earnings (P/E) ratio of 74.61 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 6.17 is lower than the industry average, implying a discounted valuation for Biomarin Pharmaceutical's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Biomarin Pharmaceutical's EV/EBITDA ratio, surpassing industry averages at 41.94, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001048477">Check Out The Full List Of Biomarin Pharmaceutical's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

RICHARD MEIER At Biomarin Pharmaceutical Capitalizes: Options Exercised, Resulting In $104K

On June 4, it was revealed in an SEC filing that ELAINE HERON, Board Member at Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) executed a significant exercise of company stock options.
What Happened: HERON, Board Member at Biomarin Pharmaceutical, made a strategic move by exercising stock options for 5,047 shares of BMRN as detailed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001048477/000104847724000118//Archives/edgar/data/1048477/000104847724000118/0001048477-24-000118-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $79,843.
Currently, Biomarin Pharmaceutical shares are trading down 0.21%, priced at $78.92 during Wednesday's morning. This values HERON's 5,047 shares at $79,843.
<h3>Get to Know Biomarin Pharmaceutical Better</h3>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Biomarin Pharmaceutical's Economic Impact: An Analysis</h3>
Revenue Growth: Biomarin Pharmaceutical displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 8.79%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a low gross margin of 80.71%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Biomarin Pharmaceutical's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.47.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.22.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: Biomarin Pharmaceutical's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 74.61.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 6.17 is lower than the industry average, implying a discounted valuation for Biomarin Pharmaceutical's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 41.94 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001048477">Check Out The Full List Of Biomarin Pharmaceutical's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELAINE HERON Exercises Options, Realizes $79K

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$40.00</td>
<td>$56.0K</td>
<td>3</td>
<td>2.9K</td>
</tr>
<tr>
<td>LFMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.50</td>
<td>$54.4K</td>
<td>2.3K</td>
<td>836</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$60.00</td>
<td>$57.5K</td>
<td>6.3K</td>
<td>664</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$110.00</td>
<td>$43.0K</td>
<td>3.0K</td>
<td>362</td>
</tr>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$30.00</td>
<td>$378.0K</td>
<td>308</td>
<td>303</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$47.50</td>
<td>$29.4K</td>
<td>1.5K</td>
<td>181</td>
</tr>
<tr>
<td>BMRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$75.00</td>
<td>$32.3K</td>
<td>525</td>
<td>68</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$115.00</td>
<td>$33.9K</td>
<td>20</td>
<td>32</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$30.00</td>
<td>$66.0K</td>
<td>1.2K</td>
<td>26</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$60.00</td>
<td>$31.9K</td>
<td>2.8K</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding CERE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>), we observe a put option trade with neutral sentiment. It expires in 45 day(s) on July 19, 2024. Parties traded 400 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $140.0 per contract. There were 3 open contracts at this strike prior to today, and today 2910 contract(s) were bought and sold. 
• For LFMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>), we notice a call option sweep that happens to be bullish, expiring in 164 day(s) on November 15, 2024. This event was a transfer of 389 contract(s) at a $7.50 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $54.4K, with a price of $140.0 per contract. There were 2327 open contracts at this strike prior to today, and today 836 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option trade that happens to be bearish, expiring in 17 day(s) on June 21, 2024. This event was a transfer of 500 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $57.5K, with a price of $115.0 per contract. There were 6331 open contracts at this strike prior to today, and today 664 contract(s) were bought and sold. 
• For ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on August 16, 2024. This event was a transfer of 336 contract(s) at a $110.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $128.0 per contract. There were 3029 open contracts at this strike prior to today, and today 362 contract(s) were bought and sold. 
• For NVAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on July 19, 2024. This event was a transfer of 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $378.0K, with a price of $1260.0 per contract. There were 308 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option sweep that happens to be bullish, expiring in 17 day(s) on June 21, 2024. This event was a transfer of 67 contract(s) at a $47.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $29.4K, with a price of $440.0 per contract. There were 1546 open contracts at this strike prior to today, and today 181 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a put option trade with bearish sentiment. It expires in 227 day(s) on January 17, 2025. Parties traded 66 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $32.3K, with a price of $490.0 per contract. There were 525 open contracts at this strike prior to today, and today 68 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option trade that happens to be bullish, expiring in 199 day(s) on December 20, 2024. This event was a transfer of 32 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $33.9K, with a price of $1060.0 per contract. There were 20 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option sweep with bullish sentiment. It expires in 227 day(s) on January 17, 2025. Parties traded 22 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $66.0K, with a price of $3000.0 per contract. There were 1261 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bullish sentiment. It expires in 17 day(s) on June 21, 2024. Parties traded 20 contract(s) at a $60.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1599.0 per contract. There were 2846 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

CERE

DXCM

EXAS

INCY

LFMD

NVAX

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Biomarin Pharmaceutical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NYSE">BMRN</a>) short percent of float has fallen 4.81% since its last report. The company recently reported that it has 3.74 million shares sold short, which is 1.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Biomarin Pharmaceutical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1716919222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Biomarin Pharmaceutical has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Biomarin Pharmaceutical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Biomarin Pharmaceutical's peer group average for short interest as a percentage of float is 6.04%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Biomarin Pharmaceutical's Recent Short Interest

These&nbsp;10&nbsp;large-cap stocks were the worst performers last week. Are they in your portfolio?
<ol>
<li>NICE Ltd&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) shares tumbled 15.60% after the company reported&nbsp;Q1&nbsp;financial results and issued&nbsp;Q2&nbsp;adjusted revenue&nbsp;guidance&nbsp;<a href="https://www.benzinga.com//node/38866576" target="_blank" rel="noreferrer noopener">with its midpoint below estimates</a>.&nbsp;</li>
<li>Petroleo Brasileiro S.A.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) shares plummeted 13.03% after&nbsp;<a href="https://www.benzinga.com//node/38818917" target="_blank" rel="noreferrer noopener">Q1 sales missed consensus</a>. Also, Brazil&#8217;s President Luiz Inacio Lula da Silva fired CEO&nbsp;Jean Paul&nbsp;Prates following a dispute&nbsp;<a href="https://www.benzinga.com//node/38850433" target="_blank" rel="noreferrer noopener">over the dividends</a>.&nbsp;</li>
<li>Comfort Systems USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) stock fell 8.37% in the last week.</li>
<li>Li Auto Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares fell 7.64%, possibly in reaction to reports that Biden is preparing tariffs on the&nbsp;<a href="https://www.benzinga.com//node/38813115" target="_blank" rel="noreferrer noopener">Chinese EV and solar sectors</a>.&nbsp;</li>
<li>Martin Marietta Materials, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) shares fell 5.23%.</li>
<li>Vulcan Materials Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>)&nbsp;share&nbsp;were down 4.89%.</li>
<li>BioMarin Pharmaceutical Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares declined 4.47% after it planned to cut 170 jobs.</li>
<li>New Oriental Education &amp; Technology Group, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>)&nbsp;<a href="https://www.benzinga.com//node/38866634" target="_blank" rel="noreferrer noopener">shares fell 4.02% last week</a>.</li>
<li>Gold Fields Limited&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) shares decreased 3.10% last week.</li>
<li>Mitsubishi UFJ Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>) shares were down 2.90% after GDP data came in worse than expected.</li>
</ol>
Read Next: <a href="https://www.benzinga.com/news/24/05/38779404/last-weeks-worst-performing-stocks-are-these-10-large-cap-stocks-in-your-portfolio-may-5-may-11-2024">Last Week&#8217;s Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (May 5-May 11, 2024)</a>

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Piper Sandler cut the price target for Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) from $290 to $238. Piper Sandler analyst Arvind Ramnani reiterated an Overweight rating. Globant shares fell 0.3% to close at $177.73 on Thursday. <a href="https://www.benzinga.com/quote/GLOB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird slashed the price target for BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) from $104 to $72. Baird analyst Joel Beatty downgraded the stock from Outperform to Neutral. BioMarin Pharmaceutical shares fell 4.3% to close at $76.97 on Thursday. <a href="https://www.benzinga.com/quote/BMRN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut Weibo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) price target from $11 to $10. Morgan Stanley analyst Alex Poon downgraded the stock from Equal-Weight to Underweight. Weibo shares rose 4.4% to close at $10.04 on Thursday. <a href="https://www.benzinga.com/quote/WB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised the price target for Rush Street Interactive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) from $9 to $10. Needham analyst Bernie McTernan maintained a Buy rating. Rush Street Interactive shares fell 1.1% to close at $8.64 on Thursday. <a href="https://www.benzinga.com/quote/RSI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) price target from $170 to $160. B of A Securities analyst Omar Dessouky maintained a Neutral rating. Take-Two Interactive shares fell 1.4% to close at $146.08 on Thursday. <a href="https://www.benzinga.com/quote/TTWO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein boosted JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) price target from $28 to $35. Bernstein analyst Robin Zhu maintained a Market Perform rating. JD.com shares rose 1.9% to close at $34.27 on Thursday. <a href="https://www.benzinga.com/quote/JD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc raised the price target for Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) from $63 to $75. Keybanc analyst Bradley Thomas maintained an Overweight rating. Walmart shares rose 7% to close at $64.01 on Thursday. <a href="https://www.benzinga.com/quote/WMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JMP Securities cut NICE Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) price target from $343 to $300. JMP Securities analyst Patrick Walravens maintained a Market Outperform rating. NICE shares fell 12.9% to close at $198.60 on Thursday. <a href="https://www.benzinga.com/quote/NICE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stephens &amp; Co. raised Advanced Drainage Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) price target from $182 to $193. Stephens &amp; Co. analyst Trey Grooms maintained an Overweight rating. Advanced Drainage Systems shares fell 2.1% to close at $172.44 on Thursday. <a href="https://www.benzinga.com/quote/WMS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities boosted Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) price target from $222 to $250. B of A Securities analyst Vivek Arya maintained a Buy rating. Applied Materials shares fell 1.6% to close at $214.03 on Thursday. <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/05/38888984/applied-materials-rbc-bearings-and-3-stocks-to-watch-heading-into-friday">Applied Materials, RBC Bearings And 3 Stocks To Watch Heading Into Friday</a>

Baird analyst Joel Beatty downgrades Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) from Outperform to Neutral and lowers the price target from $104 to $72.

Downgrades

Baird Downgrades Biomarin Pharmaceutical to Neutral, Lowers Price Target to $72

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/07/24</td>
<td>$56.00</td>
<td>$38.2K</td>
<td>765</td>
<td>2.1K</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$90.00</td>
<td>$27.8K</td>
<td>276</td>
<td>1.9K</td>
</tr>
<tr>
<td>JAZZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$110.00</td>
<td>$37.3K</td>
<td>129</td>
<td>276</td>
</tr>
<tr>
<td>NVCR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$25.00</td>
<td>$25.3K</td>
<td>446</td>
<td>220</td>
</tr>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.50</td>
<td>$37.4K</td>
<td>206</td>
<td>138</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$27.00</td>
<td>$26.9K</td>
<td>7.4K</td>
<td>128</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$780.00</td>
<td>$61.6K</td>
<td>382</td>
<td>115</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/28/24</td>
<td>$520.00</td>
<td>$36.7K</td>
<td>15</td>
<td>114</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/07/24</td>
<td>$150.00</td>
<td>$30.0K</td>
<td>115</td>
<td>103</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$120.00</td>
<td>$56.7K</td>
<td>4.4K</td>
<td>62</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option trade with bearish sentiment. It expires in 23 day(s) on June 7, 2024. Parties traded 330 contract(s) at a $56.00 strike. The total cost received by the writing party (or parties) was $38.2K, with a price of $116.0 per contract. There were 765 open contracts at this strike prior to today, and today 2101 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a call option sweep with bearish sentiment. It expires in 128 day(s) on September 20, 2024. Parties traded 105 contract(s) at a $90.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $265.0 per contract. There were 276 open contracts at this strike prior to today, and today 1969 contract(s) were bought and sold. 
• For JAZZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), we notice a put option sweep that happens to be bearish, expiring in 37 day(s) on June 21, 2024. This event was a transfer of 89 contract(s) at a $110.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $37.3K, with a price of $420.0 per contract. There were 129 open contracts at this strike prior to today, and today 276 contract(s) were bought and sold. 
• Regarding NVCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>), we observe a call option sweep with neutral sentiment. It expires in 128 day(s) on September 20, 2024. Parties traded 110 contract(s) at a $25.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $25.3K, with a price of $230.0 per contract. There were 446 open contracts at this strike prior to today, and today 220 contract(s) were bought and sold. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be bullish, expiring in 611 day(s) on January 16, 2026. This event was a transfer of 129 contract(s) at a $62.50 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $37.4K, with a price of $290.0 per contract. There were 206 open contracts at this strike prior to today, and today 138 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bullish sentiment. It expires in 93 day(s) on August 16, 2024. Parties traded 100 contract(s) at a $27.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.9K, with a price of $266.0 per contract. There were 7459 open contracts at this strike prior to today, and today 128 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be neutral, expiring in 37 day(s) on June 21, 2024. This event was a transfer of 29 contract(s) at a $780.00 strike. The total cost received by the writing party (or parties) was $61.6K, with a price of $2125.0 per contract. There were 382 open contracts at this strike prior to today, and today 115 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be neutral, expiring in 44 day(s) on June 28, 2024. This event was a transfer of 30 contract(s) at a $520.00 strike. The total cost received by the writing party (or parties) was $36.7K, with a price of $1224.0 per contract. There were 15 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 23 day(s) on June 7, 2024. This event was a transfer of 100 contract(s) at a $150.00 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $300.0 per contract. There were 115 open contracts at this strike prior to today, and today 103 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 2 day(s) on May 17, 2024. This event was a transfer of 50 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $56.7K, with a price of $1135.0 per contract. There were 4433 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JAZZ

NVCR

10 Health Care Stocks With Whale Alerts In Today's Session

BioMarin Pharmaceutical To Cut About 170 Employees

Throughout the last three months, 11 analysts have evaluated Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Biomarin Pharmaceutical, presenting an average target of $100.73, a high estimate of $113.00, and a low estimate of $85.00. This current average has increased by 1.06% from the previous average price target of $99.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1715688039_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Biomarin Pharmaceutical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Hold</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biomarin Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Biomarin Pharmaceutical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biomarin Pharmaceutical analyst ratings.</a>
<h2>Delving into Biomarin Pharmaceutical's Background</h2>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Key Indicators: Biomarin Pharmaceutical's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Biomarin Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 8.79%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 13.66%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.77%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Biomarin Pharmaceutical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.29%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average at 0.22, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Biomarin Pharmaceutical

Catalyst Watch: HP Enterprise event, Walmart+ Week, Pure Storage buzz, and triple-witching volatility

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), PT...

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), PTC Therapeutics (PTCT) and Alnylam Pharma (ALNY)

The biotech sector is primed for growth, fueled by numerous advancements in genetic engineering and rising investment in research and development of personalized medicine. Hence, quality biotech stocks, BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), and Corcept Therapeutics (CORT) with sky-high price targets might be solid buys. Read more… Over time, the prevalence of chronic diseases has risen, attributed to an increasingly sedentary lifestyle. Moreover, rising demand for biotechnology tools in agricultural applications and increasing demand for genetics and regenerative medicine bolster the biotech industry.
Given the industry's bright prospects, it could be wise to invest in fundamentally strong biotech stocks, such as BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>), Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>), and Corcept Therapeutics Incorporated (<a href="https://stocknews.com/stock/CORT/">CORT</a>), which have sky-high price targets.
The global biotechnology market is estimated to grow at a <a href="https://www.imarcgroup.com/biotechnology-market">CAGR of 6.5% to reach $1.28 trillion by 2032</a>. The market is being significantly driven by the rising investment in personalized medicine research and development, numerous advancements in genetic engineering, and the growing demand for sustainable agriculture.
Furthermore, the <a href="https://www.datamintelligence.com/research-report/biotechnology-market">increasing demand for genetics, regenerative medicine</a>, and therapy-based diagnostics is fueling the progress of the biotechnology industry. Advances in new technologies and the increasing demand for therapeutic and diagnostic solutions based on biotechnology, DNA sequencing, and recombinant technology are also bolstering the market.
Additionally, investors' interest in biotech stocks is evident from the SPDR Series Trust SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 20.9% returns over the past nine months.
Given these encouraging trends, let's look at the fundamentals of the top <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>)
BMRN develops and markets therapies for rare and life-threatening diseases such as mucopolysaccharidosis, phenylketonuria, and hemophilia. Its products target enzyme deficiencies and genetic disorders, offering hope to patients with limited treatment options.
BMRN's trailing-12-month EBIT margin of 7.61% is significantly higher than the industry average of 1.66%. Likewise, the stock's trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a> of 11.87% is 101.5% higher than the industry average of 5.89%.
BMRN's total revenue grew 8.8% year-over-year to $648.80 million in the first quarter that ended March 31, 2024. Its income from operations increased 41.8% year-over-year to $88.46 million. Its non-GAAP net income and EPS increased 20.6% and 18.3% from the prior-year quarter to $139.70 million and $0.71, respectively.
Analysts expect BMRN's revenue and EPS for the second quarter (ending June 2024) to increase 11.6% and 10.4% year-over-year to $664.36 million and $0.60, respectively. Furthermore, the company surpassed the consensus EPS estimates in three of the trailing four quarters, which is impressive.
Shares of BMRN have gained 9.2% over the past month to close the last trading session at $84.71.
Based on 21 Wall Street analysts offering 12-month price targets for BMRN in the last three months, <a href="https://www.tipranks.com/stocks/bmrn/forecast">the average target price is $108.05</a>, indicating a 27.6% change from the last price, with a high forecast of $140 and a low forecast of $72.
BMRN's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
BMRN has an A grade for Sentiment and a B for Value. BMRN is ranked #24 among 348 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/BMRN/">Click here</a> to access additional BMRN ratings (Momentum, Growth, Quality, and Stability).
Stock #2: Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>)
ALNY pioneers RNA interference-based therapeutics. Its lineup stars ONPATTRO for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria in adults, and OXLUMO fighting primary hyperoxaluria type 1.
On April 30, 2024, ALNY and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies for patients in international markets, announced a further expansion of their existing partnership in Central &amp; Eastern Europe and Israel to also include selected markets in LATAM and APAC and additional international markets.
This partnership is expected to ensure that ALNY's commercial therapies are made available across multiple international markets, thus enhancing their income streams.
On April 7, ALNY announced positive results from the KARDIA-2 Phase 2 study, which assessed the effectiveness and safety of a single subcutaneous dose of zilebesiran alongside one of three standard-of-care antihypertensive medications: indapamide, amlodipine, or olmesartan.
Zilebesiran, an investigational RNAi therapeutic, targets liver-expressed angiotensinogen (AGT) and is being developed for hypertension treatment, potentially requiring biannual dosing.
ALNY's trailing-12-month levered FCF margin of 8.63% is significantly higher than the industry average of 1.24%. Also, its trailing-12-month gross profit margin of 83.95% is 46.9% higher than the industry average of 57.14%.
During the fiscal first quarter that ended March 31, 2024, ALNY's net product revenues increased 32.1% year-over-year to $365.16 million. Its royalty revenue rose 63.4% from the year-ago value to $10.62 million. As of March 31, 2024, its total current assets stood at $2.99 billion, compared to $2.98 billion as of December 31, 2023.
Analysts predict ALNY's revenue for the fiscal second quarter ending June 2024 to increase 39.8% year-over-year to $445.48 million. Its EPS for the same quarter is expected to be $49.64. Moreover, the company has an excellent earnings surprise history, surpassing consensus EPS estimates in three of the trailing four quarters.
Over the past three months, ALNY's stock has gained 6.4% to close the last trading session at $157.40.
The stock has lost marginally intraday to close the last trading session at $40.49. Based on 16 Wall Street analysts offering 12-month price targets for ALNY in the last three months, <a href="https://www.tipranks.com/stocks/alny/forecast">the average target price is $225</a>, indicating a 43% change from the last price, with a high forecast of $400 and a low forecast of $138.
ALNY's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
ALNY has a B grade for Quality, Sentiment, and Growth. It is ranked #21 in the same industry.
In addition to the POWR Ratings we've stated above, we also have ALNY ratings for Momentum, Value, and Stability. Get all ALNY ratings <a href="https://stocknews.com/stock/ALNY/">here</a>.
Stock #1: Corcept Therapeutics Incorporated (<a href="https://stocknews.com/stock/CORT/">CORT</a>)
CORT discovers and develops drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients and those who have type 2 diabetes mellitus or glucose intolerance.
CORT's trailing-12-month asset turnover ratio of 0.82x is 103.2% higher than the industry average of 0.40x. Similarly, its trailing-12-month EBIT margin and levered FCF margin of 23.29% and 23.66% are considerably higher than the industry averages of 1.66% and 1.24%, respectively.
For the fiscal first quarter that ended March 31, 2024, CORT's net product revenue and income from operations stood at $146.81 million and $29.50 million, up 39% and 98.6% year-over-year, respectively. For the same quarter, its net income attributable to common stockholders and net income per common share increased 74.1% and 78.6% from the year-ago quarter to $27.51 million and $0.25, respectively.
Street expects CORT's fiscal 2025 EPS to increase 46.2% year-over-year to $1.35. Its revenue for the quarter ending June 30, 2024, is expected to grow 31.9% year-over-year to $155.22 million. The company surpassed consensus EPS and revenue estimates in each of the trailing four quarters.
CORT has gained 20.4% over the past three months, closing the last trading session at $29.40.
The stock lost marginally intraday to close the last trading session at $40.49. Based on five Wall Street analysts offering 12-month price targets for CORT in the last three months, <a href="https://www.tipranks.com/stocks/cort/forecast">the average target price is $49.70</a>, indicating a 69.1% change from the last price, with a high forecast of $70.50 and a low forecast of $35.
CORT's POWR Ratings reflect its promising outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
The stock has an A grade for Quality and a B for Value. Within the same industry, CORT is ranked #17 in the same industry.
<a href="https://stocknews.com/stock/CORT/">Click here</a> to access additional ratings of CORT for Stability, Growth, Sentiment, and Momentum.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ALNY shares were trading at $163.93 per share on Friday afternoon, up $6.53 (+4.15%). Year-to-date, ALNY has declined -14.36%, versus a 14.83% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/alny-bmrn-cort-3-biotech-stocks-with-sky-high-price-targets/>3 Biotech Stocks With Sky-High Price Targets</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks With Sky-High Price Targets

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immutep (IMMP – Research Report) and BioMarin Pharma...

Wall Street Analysts Are Bullish on Top Healthcare Picks

BMO sees BMRN, LEGN, SLN as attractive M&A targets

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), wit...


Daniel GoldmanHouse (D-NY)	$1K - $15K	stock	Sale	Apr 17, 2023	Mar 06, 2023	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale	Nov 15, 2021	Oct 18, 2021	House

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government Trades

Biomarin Pharmaceutical Inc

top performing BMRN trades